Alpha Tau Medical Management
Management criteria checks 4/4
We currently do not have sufficient information about the CEO.
Key information
Uzi Sofer
Chief executive officer
US$630.0k
Total compensation
| CEO salary percentage | 100.0% |
| CEO tenure | 10yrs |
| CEO ownership | 16.5% |
| Management average tenure | 6yrs |
| Board average tenure | 8yrs |
Recent management updates
Recent updates
Alpha Tau Medical (NASDAQ:DRTS) Has Debt But No Earnings; Should You Worry?
May 25
Alpha Tau Medical (NASDAQ:DRTS) Is In A Good Position To Deliver On Growth Plans
Nov 08Alpha Tau director gives up board seat to take up chief commercial officer role
Sep 02Alpha Tau Medical GAAP EPS of -$0.03
Aug 25Alpha Tau: Treating Cancer With Precision Alpha Radiation
Apr 12CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$30m |
| Jun 30 2024 | n/a | n/a | -US$28m |
| Mar 31 2024 | n/a | n/a | -US$29m |
| Dec 31 2023 | US$630k | US$630k | -US$29m |
| Sep 30 2023 | n/a | n/a | -US$25m |
| Jun 30 2023 | n/a | n/a | -US$23m |
| Mar 31 2023 | n/a | n/a | -US$16m |
| Dec 31 2022 | US$3m | US$628k | -US$34m |
Compensation vs Market: Uzi's total compensation ($USD630.00K) is below average for companies of similar size in the US market ($USD1.38M).
Compensation vs Earnings: Uzi's compensation has been consistent with company performance over the past year.
CEO
Uzi Sofer (54 yo)
10yrs
Tenure
US$630,000
Compensation
Mr. Uzi Sofer serves as Chief Executive Officer and Chairman at Alpha Tau Medical LTD (Alternate name Healthcare Capital Corp.) since 2015. He founded Brainsway Ltd., in 2006 and served as its Chief Execut...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman | 10yrs | US$630.00k | 16.47% $ 36.0m | |
| Chief Financial Officer | 6yrs | US$424.00k | 0% $ 0 | |
| Chief Operations Officer | 7yrs | US$340.00k | 0.098% $ 214.3k | |
| Chief Commercial Officer | 2.3yrs | US$376.00k | 0% $ 0 | |
| Chief Medical Officer & Member of Scientific Advisory Board | 5.3yrs | US$401.00k | 0% $ 0 | |
| Chief Technology Officer | 6yrs | US$705.00k | 0% $ 0 | |
| Chief Scientific Officer & Member of Scientific Advisory board | 5.3yrs | no data | 0.72% $ 1.6m | |
| Vice President of legal | no data | no data | no data | |
| Chief Physics Officer & Member of Scientific Advisory Board | 9yrs | no data | 1.9% $ 4.2m | |
| Corporate Controller | no data | no data | no data |
6.0yrs
Average Tenure
51yo
Average Age
Experienced Management: DRTS's management team is seasoned and experienced (6 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Chairman | 10yrs | US$630.00k | 16.47% $ 36.0m | |
| Chief Medical Officer & Member of Scientific Advisory Board | no data | US$401.00k | 0% $ 0 | |
| Chief Scientific Officer & Member of Scientific Advisory board | 5.3yrs | no data | 0.72% $ 1.6m | |
| Chief Physics Officer & Member of Scientific Advisory Board | no data | no data | 1.9% $ 4.2m | |
| Independent Director | 2.8yrs | no data | 0% $ 0 | |
| Independent Director | 7yrs | no data | 0% $ 0 | |
| Independent Director | 2.8yrs | no data | 0.41% $ 903.9k | |
| Independent Director | 9yrs | no data | 0.11% $ 234.8k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 9yrs | no data | 0.067% $ 147.4k | |
| Director | 9yrs | no data | 2.17% $ 4.8m | |
| Member of Scientific Advisory Board | no data | no data | no data |
8.0yrs
Average Tenure
70yo
Average Age
Experienced Board: DRTS's board of directors are considered experienced (8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/06 16:20 |
| End of Day Share Price | 2025/01/03 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Alpha Tau Medical Ltd. is covered by 6 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Kristen Kluska | Cantor Fitzgerald & Co. |
| Yigal Nochomovitz | Citigroup Inc |
| Neena Bitritto-Garg | Citigroup Inc |